Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of novel coronavirus disease 2019 (COVID-19), has become a severe threat to global public health. There are currently no antiviral therapies approved for the treatment or prevention of mild to moderate COVID-19 as remd...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Ashley N., Strobel, Gary, Hanrahan, Kaley C., Sears, Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999574/
https://www.ncbi.nlm.nih.gov/pubmed/33807769
http://dx.doi.org/10.3390/v13030415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999574/
https://www.ncbi.nlm.nih.gov/pubmed/33807769
http://dx.doi.org/10.3390/v13030415

Ejemplares similares